{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:21:02Z","timestamp":1770441662189,"version":"3.49.0"},"reference-count":63,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016098","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:36:37Z","timestamp":1751956597000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complement inhibitors for myasthenia gravis in adults"],"prefix":"10.1002","volume":"2025","author":[{"given":"Laura M","family":"White","sequence":"additional","affiliation":[{"name":"Lancaster Medical School; Lancaster University; Lancaster UK"},{"name":"Department of Neurology; Lancashire Teaching Hospitals NHS Foundation Trust; Preston UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona J","family":"Clay","sequence":"additional","affiliation":[{"name":"Department of Forensic Medicine; Monash University; Southbank Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Forbes","sequence":"additional","affiliation":[{"name":"Creative Arts & Health - School of Creative Arts & Media; University of Tasmania; Hobart Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan Yann Shern","family":"Keh","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford, Greater Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B","family":"Lilleker","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford, Greater Manchester UK"},{"name":"Manchester Academic Health Sciences Centre; The University of Manchester; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Spillane","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; University College London Hospitals NHS Foundation Trust; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Storms","sequence":"additional","affiliation":[{"name":"Library & Knowledge Service; Northern Care Alliance NHS Foundation Trust; Oldham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Sussman","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford, Greater Manchester UK"},{"name":"Manchester Academic Health Sciences Centre; The University of Manchester; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine C","family":"Dodd","sequence":"additional","affiliation":[{"name":"Manchester Centre for Clinical Neurosciences; Northern Care Alliance NHS Foundation Trust; Salford, Greater Manchester UK"},{"name":"Manchester Academic Health Sciences Centre; The University of Manchester; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD016098-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD016098-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539577","article-title":"Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review","volume":"9","author":"Sciancalepore","year":"2024","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1002\/14651858.CD016098-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD016098-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nature Reviews Immunology"},{"issue":"10","key":"10.1002\/14651858.CD016098-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archneur.57.4.527","article-title":"Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia","volume":"57","author":"Mygland","year":"2020","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11748-007-0185-8","article-title":"Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis","volume":"56","author":"Okumura","year":"2008","journal-title":"General Thoracic and Cardiovascular Surgery"},{"issue":"2","key":"10.1002\/14651858.CD016098-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clinical and Experimental Immunology"},{"issue":"6","key":"10.1002\/14651858.CD016098-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement deposition at the neuromuscular junction in seronegative myasthenia gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathologica"},{"key":"10.1002\/14651858.CD016098-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48","author":"Berrih-Aknin","year":"2014","journal-title":"Journal of Autoimmunity"},{"key":"10.1002\/14651858.CD016098-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Practical Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016098-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD016098-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD016098-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD016098-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD016098-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016098-BIB0017|cit17","first-page":"e16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"20","author":"Sacc\u00e0","year":"2023","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016098-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD016098-BIB0019|cit19","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale Journal of Biology Medicine"},{"issue":"6","key":"10.1002\/14651858.CD016098-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp-2022-330519","article-title":"Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis","volume":"94","author":"Uzawa","year":"2023","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD016098-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Frontiers in Neurology"},{"issue":"1","key":"10.1002\/14651858.CD016098-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","year":"2018","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD016098-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair","year":"2023","journal-title":"Immunotargets and Therapy"},{"key":"10.1002\/14651858.CD016098-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"175628642093569","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1002\/14651858.CD016098-BIB0026|cit26","unstructured":"Soliris\u00ae (eculizumab) concentrated solution for intravenous infusion Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125166s172lbl.pdf"},{"key":"10.1002\/14651858.CD016098-BIB0027|cit27","unstructured":"European Medicines Agency Soliris\u00ae summary of product characteristics Available at ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf"},{"key":"10.1002\/14651858.CD016098-BIB0028|cit28","unstructured":"Ultomiris\u00ae (ravulizumab-cwvz) concentrated solution for intraveouns infusion Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf"},{"key":"10.1002\/14651858.CD016098-BIB0029|cit29","unstructured":"European Medicines Agency Ultomiris\u00ae summary of product characteristics Available at ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf"},{"key":"10.1002\/14651858.CD016098-BIB0030|cit30","unstructured":"Zilbrysq (zilucoplan) injection, for subcutaneous use Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf"},{"key":"10.1002\/14651858.CD016098-BIB0031|cit31","unstructured":"A study to test how safe pozelimab and cemdisiran combination therapy and cemdisiran alone are and how well they work in adult patients with generalized myasthenia gravis (NIMBLE) clinicaltrials.gov\/study\/NCT05070858"},{"key":"10.1002\/14651858.CD016098-BIB0032|cit32","unstructured":"Study of ALXN2050 in adult participants with generalized myasthenia gravis clinicaltrials.gov\/study\/NCT05218096"},{"key":"10.1002\/14651858.CD016098-BIB0033|cit33","unstructured":"Safety and efficacy of ALXN1720 in adults with generalized myasthenia gravis clinicaltrials.gov\/study\/NCT05556096"},{"issue":"6","key":"10.1002\/14651858.CD016098-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2017.03.009","article-title":"Therapeutic inhibition of complement: well worth the risk","volume":"38","author":"Barnum","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD016098-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/jcm8030407","article-title":"The extended use of eculizumab in pregnancy and complement activation - associated diseases affecting maternal, fetal and neonatal kidneys - the future is now?","volume":"8","author":"Stefanovic","year":"2019","journal-title":"Journal of Clinical Medicine"},{"key":"10.1002\/14651858.CD016098-BIB0036|cit36","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews (MECIR). Version August 2023. Cochrane, London community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016098-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD016098-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Barohn","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Utsugisawa","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Barohn","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"7","key":"10.1002\/14651858.CD016098-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1002\/14651858.CD016098-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1002\/14651858.CD016098-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1002\/14651858.CD016098-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle and Nerve"},{"issue":"18","key":"10.1002\/14651858.CD016098-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG Composite: a valid and reliable tool for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD016098-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle and Nerve"},{"key":"10.1002\/14651858.CD016098-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD016098-BIB0049|cit49","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD016098-BIB0050|cit50","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD016098-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD016098-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016098-BIB0053|cit53","unstructured":"Outcome Reporting Bias in Trials (ORBIT) Welcome to the ORBIT website Available at outcome-reporting-bias.org"},{"key":"10.1002\/14651858.CD016098-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"7109","key":"10.1002\/14651858.CD016098-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016098-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016098-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016098-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016098-BIB0059|cit59","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD016098-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12883-016-0756-3","article-title":"Response to treatment of myasthenia gravis according to clinical subtype","volume":"16","author":"Akaishi","year":"2016","journal-title":"BMC Neurology"},{"key":"10.1002\/14651858.CD016098-BIB0061|cit61","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD016098-BIB0062|cit62","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (last updated May 2025). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016098-BIB0063|cit63","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:36:48Z","timestamp":1751956608000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016098"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":63,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016098","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}